pany participated in the China's National R&D Program's selection
and evaluation process. Sinovac was selected by the government to take charge
of the research and development program for the varicella (chickenpox) vaccine.
As an acute infectious disease, varicella often breaks out among the pediatric
population and can lead to serious conditions such as pneumonia, encephalitis,
and even death. This disease leads to serious symptoms among adult as well.
The fatality rate in adults is as high as 30-40 times that of children between
5-9 years old. According to a report by the Children Hospital of Shanghai,
current incidence rate among children is four times greater than rates
reported in the 1980s. The domestic market in China is in a development phase
with an annual demand of 10 million doses. Once the vaccine is successfully
launched, Sinovac would provide the Chinese market with a new vaccine against
varicella and the herpes zoster virus.
During the third quarter, Sinovac advanced the development of its split
pandemic influenza vaccine. The Company completed volunteer enrollment and
dosing in its Phase II double-blind trial of the split pandemic influenza
vaccine. The second shot was administered to 472 healthy volunteers in
September, inclusive of 263 adolescents, 138 pediatrics and 71 geriatrics.
The vaccination process to volunteers has been completed and the Company is
currently collecting data and preparing the analysis. It is anticipated that
the preliminary results will be available in early 2009.
In October 2008, Sinovac was named to the Deliotte Technology Fast 50
China 2008 based on its high growth rate of 290% over the past three years.
The ranking recognizes the 50 fastest growing life sciences, technology, media
and telecommunications in China.
Conference Call Details
The Company will host a conference call on Tuesday, November 18, 2008 at
8:00 p.m. ET to review Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related biology technology :1
. Sinovac Named to Deloitte Technology Fast 50 China2
. Sinovac to Participate in Two Upcoming Investor Conferences3
. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating4
. Sinovac Biotech Holds 2007 Annual General Meeting5
. Sinovac to Present at the 2008 UBS Global Life Sciences Conference6
. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine7
. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season8
. Sinovac Adjourns Annual General Meeting9
. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference10
. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results11
. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders